Adagene Announced New ADG126 Clinical Data From From Ongoing Phase 1b/2 Trial Of SAFEbody Plus Keytruda Combo
Presented At The ESMO Congress
Portfolio Pulse from Benzinga Newsdesk
Adagene presented new clinical data at the ESMO Congress for its ADG126 and Keytruda combination, showing improved response rates and survival in certain cancer patients. The combination maintained a favorable safety profile.
September 16, 2024 | 9:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adagene's ADG126 in combination with Keytruda shows promising clinical trial results, doubling partial responses and improving survival rates in certain cancer patients. The safety profile remains favorable, indicating potential for broader patient use.
The clinical trial results presented by Adagene show significant improvements in response rates and survival for patients treated with ADG126 and Keytruda. The doubling of partial responses and favorable safety profile suggest positive market sentiment and potential stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90